Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 4:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 7,459 matching trials from the live ClinicalTrials.gov search.
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
Elsubrutinib, Placebo for elsubrutinib, Upadacitinib, Placebo for upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
47
States / cities
Mesa, Arizona • Phoenix, Arizona • Jonesboro, Arkansas + 40 more
Conditions
Coronavirus Disease 2019 (COVID-19)
Interventions
Rivaroxaban, Placebo, Standard of Care (SOC)
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
17
States / cities
Tucson, Arizona • Los Angeles, California • Oakland, California + 13 more
Conditions
Biliary Tract Cancer
Interventions
Rilvegostomig, Placebo, Capecitabine, Gemcitabine/Cisplatin, S-1 [Tegafur/Oteracil/gimeracil]
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
760 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more
Conditions
Breast Neoplasms, Breast Cancer, Metastasis
Interventions
CAL
Drug
Lead sponsor
Chugai Pharma USA
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
38
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Concord, California + 32 more
Conditions
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
Interventions
Ralinepag, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
687 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
68
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more
Conditions
Male Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Cixutumumab, Laboratory Biomarker Analysis, Pharmacological Study, Temsirolimus
Biological · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
192
States / cities
Palo Alto, California • Pleasanton, California • Aurora, Colorado + 123 more
Conditions
Lumbar Puncture, Topical Analgesia
Interventions
J-Tip, EMLA, Lidocaine
Device · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
Up to 18 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Best Practice, Exercise Counseling, Exercise Intervention, Magnetic Resonance Imaging, Neuropathy Assessment, Questionnaire Administration
Other · Procedure
Lead sponsor
University of Rochester NCORP Research Base
Other
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
93
States / cities
Fresno, California • Martinez, California • Roseville, California + 70 more
Conditions
Dravet Syndrome
Interventions
LP352, Placebo
Drug
Lead sponsor
Longboard Pharmaceuticals
Industry
Eligibility
2 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
25
States / cities
Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 20 more
Conditions
Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Higher-Risk Myelodysplastic Syndrome (HR-MDS), Acute Myeloid Leukemia (AML), Newly Diagnosed Intermediate/High-Risk MDS
Interventions
KPT-8602, ASTX727, Dexamethasone
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
26
States / cities
Los Angeles, California • Pasadena, California • Aurora, Colorado + 23 more
Conditions
AML, MDS
Interventions
SOC + TSC-101, Control, SOC + TSC-100
Drug · Other
Lead sponsor
TScan Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
21
States / cities
Duarte, California • Aurora, Colorado • Denver, Colorado + 16 more
Conditions
Crohn's Disease
Interventions
certolizumab pegol
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
6 Years to 17 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
7
States / cities
Orange, California • Aurora, Colorado • Atlanta, Georgia + 3 more
Conditions
Childhood Hepatocellular Carcinoma, Childhood Malignant Liver Neoplasm, Fibrolamellar Carcinoma, Hepatoblastoma, Hepatocellular Malignant Neoplasm, Not Otherwise Specified
Interventions
Biospecimen Collection, Carboplatin, Cisplatin, Doxorubicin, Etoposide, Fluorouracil, Gemcitabine, Irinotecan, Oxaliplatin, Patient Observation, Resection, Sorafenib, Vincristine Sulfate
Procedure · Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
180
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 134 more
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine/Zidovudine, Nelfinavir mesylate, Efavirenz
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
49
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 32 more
Conditions
Biliary Atresia
Interventions
Intravenous immunoglobulin (IVIG)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
3 Days to 120 Days
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 3 more
Completed Not applicable Interventional Results available

Non-Complex Biliary Stones DSC vs ERC

NCT03421340
Conditions
Biliary Stones
Interventions
DSC, ERC
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Stanford, California • Aurora, Colorado • New Orleans, Louisiana + 1 more
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Nicole Hamblett
Other
Eligibility
12 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
68
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more
Conditions
HIV Infections
Interventions
Stavudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 6 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
51
States / cities
Long Beach, California • Los Angeles, California • Oakland, California + 37 more
Conditions
Colonic Neoplasms
Interventions
Not listed
Lead sponsor
Metabiomics Corp
Industry
Eligibility
18 Years to 95 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Renal Transplant Patients
Interventions
Envarsus XR
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Lung Neoplasms, Lung Cancer
Interventions
Radiation therapy
Radiation
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
Aurora, Colorado • Royal Oak, Michigan
Conditions
Glioblastoma, Gliosarcoma
Interventions
Temozolomide, Depatuxizumab mafodotin, Radiation, Placebo for ABT-414
Drug · Radiation
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
691 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
68
States / cities
Phoenix, Arizona • Springdale, Arkansas • Los Angeles, California + 52 more
Conditions
Prostate Cancer
Interventions
Enzalutamide, Bicalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
109
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 76 more
Conditions
Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), TP53-mutated MDS and AML
Interventions
CLN-049
Drug
Lead sponsor
Cullinan Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 13 more